Treating type 2 diabetes in renal insufficiency: The role of pioglitazone

International Journal of Clinical Pharmacology and Therapeutics

Volumn 41, Issue 10, 2003, Pages 488-491

  Fritsche, Lutz ^a   Budde, K ^a   Glander, P ^a   Einecke, G ^a   Diekmann, F ^a   Schotschel R ^a   Neumayer, H H ^a  

^a Department of Nephrology ^*  (Germany)

Author keywords

Diabetes; Pioglitazone; Renal disease; Side effects; Therapy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; DIURETIC AGENT; DRUG METABOLITE; GLIBENCLAMIDE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TROGLITAZONE;

ANEMIA; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; EDEMA; FLUID RETENTION; HEART FAILURE; HUMAN; HYPOGLYCEMIA; INSULIN RESPONSE; KIDNEY FAILURE; KIDNEY FUNCTION; LACTIC ACIDOSIS; LIVER; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; TARGET ORGAN; WEIGHT GAIN;

EID: 0141996219     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP41488     Document Type: Review

References (14)

1. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL 2000 Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized, placebo-controlled, dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 23: 1605-1611
2. Budde K, Neumayer H-H, Fritsche L, Sulowicz W, Stompor T, Eckland D 2003 The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 55: 368-374
3. Eckland DA, Danhof M 2000 Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diab 108 (Suppl 2): S234-S242
4. Fuchtenbusch M, Standl E, Schatz H 2000 Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diab 108: 151-163
5. Gan SC, Barr J, Arieff AI, Pearl RG 1992 Biguanide-associated lactic acidosis. Case report and review of the literature. Arch Intern Med 152: 2333-2336
6. Gilbert RE, Tsalamandris C, Bach LA, Panagiotopoulos S, O'Brien RC, Allen TJ, Goodall I, Young V, Seeman E, Murray RM et al 1993 Long-term glycemic control and the rate of progression of early diabetic kidney disease. Kidney Int 44: 855-859
7. Hatorp V, Oliver S, Su CA 1998 Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers. Int J Clin Pharmacol Ther 36: 636-641 http://Www.fda.gov/medwatch/SAFETY/2002/summary-actos-avandia.PDF
8. Lebovitz HE 2002 Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 18: S23-S29
9. Maeda K 2001 Hepatocellular injury in a patient receiving pioglitazone. Ann Intern Med 135: 306
10. May LD, Lefkowitch JH, Kram MT, Rubin DE 2002 Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med 136: 449-452
11. Parke-Davis 1999 Rezulin (troglitazone) tablets. Prescribing information. Morris Plains, NJ
12. Ritz E, Orth SR 1999 Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 341: 1127-1133
13. Takeda Pharmaceuticals America Inc 1999 Actos (pioglitazone hydrochloride) tablets. Prescribing information. Takeda Pharmaceuticals America, Lincolnshire, IL
14. Yamasaki Y, Kawamori R, Wasada T et al 1997 Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan. Tohoku J Exp Med 183: 173-183